Rajesh Bajaj, MD
Hematology & Oncology · Florence, SCNPI 1972543643
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,223 of the $10,300 with a category attached, or 60.4%. 46 manufacturers reported payments, led by Beigene USA, Inc. at 27.2% of the total. Reporting peaked in 2023 at $4,990 and has fallen 83.3% since, to $835 in 2025.
Across 168 payments — averaging $61.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$3K
- AstraZeneca$2K
- Janssen Scientific Affairs, LLC$1K
- Beigene, Ltd.$525
- EMD Serono, Inc.$512
- Novartis$316
- plus $3K from 40 others
Across 24 payments — averaging $4948.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$110K
- Puma Biotechnology, Inc.$4K
- Bayer$3K
- Merck$2K
What the payments were for
- Consulting fees$6,22360%
- Speaking & faculty fees$2002%
- Food & beverage$3,45934%
- Education$4184%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$3,325
- DARZALEX$1,010
- Tepmetko$500
- GENERAL VASCULAR ACCESS$108
- Da Vinci Surgical System$102
How this compares
$10,300 in reported general payments places this provider in the 70th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 152 | $2,161,408 |
| Lenalidomide | 113 | $1,754,177 |
| ImbruvicaIbrutinib | 96 | $1,628,986 |
| RevlimidLenalidomide | 45 | $857,609 |
| TagrissoOsimertinib Mesylate | 38 | $659,870 |
| CalquenceAcalabrutinib Maleate | 47 | $637,729 |
| VerzenioAbemaciclib | 43 | $611,838 |
| KisqaliRibociclib Succinate | 33 | $604,048 |
| SprycelDasatinib | 35 | $537,936 |
| PomalystPomalidomide | 20 | $493,616 |
| CabometyxCabozantinib S-Malate | 16 | $379,422 |
| ErleadaApalutamide | 22 | $312,834 |
| Abiraterone Acetate | 58 | $203,666 |
| VenclextaVenetoclax | 15 | $167,228 |
| GleevecImatinib Mesylate | 14 | $139,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $220 | $2,161,408152 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $16 | $1,628,98696 claims |
| AstraZenecaTagrisso, Calquence | $1,630 | $1,297,59885 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $204 | $1,031,55355 claims |
| Bristol Myers SquibbRevlimid | $192 | $857,60945 claims |
| NovartisKisqali, Gleevec | $316 | $743,49047 claims |
| Lilly USA, LLCVerzenio | $198 | $611,83843 claims |
| Exelixis Inc.Cabometyx | $57 | $379,42216 claims |
| Johnson & JohnsonErleada, Xarelto | $270 | $329,76149 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,048 | $203,66658 claims |
| AbbVieVenclexta | $27 | $167,22815 claims |
| Beigene USA, Inc.Brukinsa | $2,800 | $90,30612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Florence
- Mark KeatonFlorence$26K
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Bhumika PatelGreenville$225K
- Ming LimCharleston$94K
- George GeilsCharleston$76K
- Joe StephensonGreenville$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.